Professor He Jianxing: Lung Cancer and Minimally Invasive Thoracic Surgery Specialist
Professor He Jianxing is a senior thoracic surgeon, professor, and clinical leader at the First Affiliated Hospital of Guangzhou Medical University. His work focuses on lung cancer surgery, single-port thoracoscopy, complex airway reconstruction, perioperative innovation, and selected lung-transplant assessment.
Clinical and Academic Focus
- early and locally advanced lung cancer;
- single-port and minimally invasive thoracic surgery;
- segmentectomy and lobectomy;
- complex central lung tumors;
- bronchial and vascular sleeve reconstruction;
- mediastinal tumors;
- complex or repeat chest surgery;
- lung transplantation assessment; and
- second opinions on surgical eligibility.
Early Lung Cancer
Small lung nodules and early lung cancers require careful review of CT appearance, growth, size, solid component, location, and patient risk. Not every nodule requires immediate surgery, while persistent or changing suspicious lesions may need biopsy or resection.
For operable early non-small cell lung cancer, surgery may involve wedge resection, anatomical segmentectomy, or lobectomy with lymph-node assessment. The choice balances cancer control with preservation of lung function.
Single-Port Thoracoscopic Surgery
Single-port video-assisted thoracic surgery uses one main incision for the camera and instruments. In selected patients it may reduce surgical trauma and support recovery, but it does not automatically make a complex operation safer.
The priority remains complete tumor removal, appropriate lymph-node evaluation, bleeding control, and protection of vital structures. Conversion to an additional incision or open surgery can be the safest decision when required.
Segmentectomy and Lobectomy
Segmentectomy removes an anatomical portion of a lung lobe, while lobectomy removes the entire lobe. Segmentectomy may be appropriate for selected small peripheral cancers, limited lung reserve, or multiple lesions.
Tumor size, location, margins, lymph nodes, pathology, and pulmonary function all influence the decision. A smaller operation is not necessarily adequate for every early cancer.
Complex Airway Reconstruction
Central tumors can involve a major bronchus or nearby pulmonary vessels. Sleeve resection removes the involved segment and reconnects the airway or vessel, potentially avoiding removal of an entire lung.
These procedures require careful imaging, bronchoscopy, cardiopulmonary assessment, and surgical expertise. They are not suitable when tumor extent prevents complete and safe reconstruction.
Treatment Before and After Surgery
Selected patients with locally advanced lung cancer may receive chemotherapy, immunotherapy, targeted therapy, or a combination before surgery. Postoperative treatment depends on stage, lymph nodes, margins, driver alterations, and pathological response.
Surgery after induction treatment can be technically more demanding and should be planned by a multidisciplinary thoracic oncology team.
Lung Transplantation
Lung transplantation may be considered for selected patients with advanced non-malignant lung disease when other treatments no longer provide adequate survival or quality of life. Active cancer usually affects eligibility because immunosuppression can increase recurrence risk.
Evaluation includes diagnosis, expected prognosis, infection status, heart and organ function, rehabilitation potential, psychosocial support, adherence, and donor availability. Acceptance cannot be determined from records alone.
Who May Consider a Consultation?
- patients with an early or potentially operable lung cancer;
- patients comparing segmentectomy and lobectomy;
- patients considering single-port or another minimally invasive approach;
- patients with a central tumor requiring airway or vascular reconstruction;
- patients needing surgery after induction treatment;
- patients with multiple lung nodules or previous chest surgery;
- patients with limited pulmonary reserve; or
- patients seeking lung-transplant evaluation for advanced non-malignant disease.
Medical Records to Prepare
- a concise medical summary and treatment timeline;
- thin-slice chest CT, PET-CT, and brain MRI in original DICOM format;
- pathology reports, glass slides, and paraffin blocks;
- molecular and PD-L1 reports for lung cancer;
- bronchoscopy and airway imaging;
- pulmonary-function, exercise, and cardiac assessments;
- previous operative and radiotherapy records;
- systemic treatment details with response imaging;
- recent blood tests and infection screening; and
- a clear list of questions about surgical extent, risk, and recovery.
Planning an International Consultation
Before travel, patients should confirm whether imaging and pathology can be reviewed and whether additional staging is required. Remote medical-record review requires physician authorization. Final surgical or transplant eligibility, approach, timing, hospital stay, and cost require complete assessment by the treating team.
How CMCS Can Assist
CMCS – China Medical Concierge Shanghai is an independent medical concierge and health management company, not a hospital. We assist international patients with organizing and translating thoracic records, identifying an appropriate specialist, requesting appointment availability, arranging interpretation, and planning medical travel in China.
Access to Professor He, remote review, surgery, or transplant evaluation is subject to doctor and hospital approval. CMCS does not guarantee appointments, surgical eligibility, transplant acceptance, donor availability, or clinical outcomes.
- Email: contract@medicalsh.com
- WhatsApp: Contact us on WhatsApp
- Website: www.medicalsh.com
Important Note
Doctor roles, surgical techniques, transplant criteria, treatment availability, and appointment arrangements may change. This profile is for general information only and does not replace assessment by a qualified thoracic team.
0 commenti